Catalyst Pharmaceuticals Company Profile (NASDAQ:CPRX)

About Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals logoCatalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CPRX
  • CUSIP: N/A
  • Web: www.catalystpharma.com
Capitalization:
  • Market Cap: $213.08 million
  • Outstanding Shares: 84,554,000
Average Prices:
  • 50 Day Moving Avg: $2.58
  • 200 Day Moving Avg: $2.43
  • 52 Week Range: $0.94 - $3.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.08
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.40 per share
  • Price / Book: 6.30
Profitability:
  • EBITDA: ($16,440,000.00)
  • Return on Equity: -44.65%
  • Return on Assets: -42.03%
Debt:
  • Current Ratio: 19.43%
  • Quick Ratio: 19.43%
Misc:
  • Average Volume: 659,616 shs.
  • Beta: 1.59
  • Short Ratio: 5.67
 

Frequently Asked Questions for Catalyst Pharmaceuticals (NASDAQ:CPRX)

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its earnings results on Wednesday, August, 9th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.01. View Catalyst Pharmaceuticals' Earnings History.

When will Catalyst Pharmaceuticals make its next earnings announcement?

Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Catalyst Pharmaceuticals.

Where is Catalyst Pharmaceuticals' stock going? Where will Catalyst Pharmaceuticals' stock price be in 2017?

4 brokerages have issued twelve-month price targets for Catalyst Pharmaceuticals' shares. Their forecasts range from $5.00 to $6.00. On average, they anticipate Catalyst Pharmaceuticals' share price to reach $5.50 in the next twelve months. View Analyst Ratings for Catalyst Pharmaceuticals.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a decrease in short interest during the month of September. As of September 15th, there was short interest totalling 4,220,460 shares, a decrease of 35.4% from the August 31st total of 6,532,907 shares. Based on an average daily volume of 856,492 shares, the days-to-cover ratio is presently 4.9 days. Approximately 5.9% of the company's stock are short sold.

Who are some of Catalyst Pharmaceuticals' key competitors?

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the folowing people:

  • Patrick James McEnany, Chairman of the Board, President, Chief Executive Officer
  • Alicia Grande CPA, Chief Financial Officer, Vice President, Treasurer
  • Steven R. Miller Ph.D., Chief Operating Officer, Chief Scientific Officer
  • David D. Muth, Executive Vice President, Chief Commercial Officer
  • M. Douglas Winship, Vice President - Regulatory Operations
  • David J. Caponera, Vice President - Patient Advocacy & Reimbursement
  • Bernardino Mosquera M.D., Vice President - Clinical Operations
  • Charles B. O'Keeffe, Lead Independent Director
  • Gary Ingenito M.D., Chief Medical Officer
  • Richard J. Daly, Director

How do I buy Catalyst Pharmaceuticals stock?

Shares of Catalyst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of Catalyst Pharmaceuticals stock can currently be purchased for approximately $2.52.


MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  243
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Catalyst Pharmaceuticals (NASDAQ:CPRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.50 (118.25% upside)
Consensus Price Target History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Price Target History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Analysts' Ratings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/5/2017SunTrust Banks, Inc.Reiterated RatingBuy$5.00HighView Rating Details
8/10/2017Roth CapitalSet Price TargetBuy$5.00LowView Rating Details
8/7/2017Piper Jaffray CompaniesSet Price TargetBuy$6.00LowView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$6.00LowView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Earnings by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Earnings History by Quarter for Catalyst Pharmaceuticals (NASDAQ CPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.06)N/AView Earnings Details
8/9/2017Q2 2017($0.06)($0.05)ViewListenView Earnings Details
5/10/2017Q1 2017($0.06)($0.06)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.07)($0.05)ViewN/AView Earnings Details
11/9/2016Q316($0.06)($0.05)ViewListenView Earnings Details
8/9/2016Q216($0.08)($0.06)ViewN/AView Earnings Details
5/10/2016Q116($0.07)($0.07)ViewN/AView Earnings Details
3/15/2016Q415($0.07)($0.07)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.06)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.06)ViewN/AView Earnings Details
3/16/2015Q414($0.07)($0.06)ViewN/AView Earnings Details
11/14/2014Q314($0.06)($0.06)ViewN/AView Earnings Details
8/14/2014Q214($0.08)($0.05)ViewN/AView Earnings Details
3/19/2014Q413($0.07)($0.02)ViewN/AView Earnings Details
11/14/2013Q3($0.07)($0.07)ViewN/AView Earnings Details
8/15/2013Q213($0.07)($0.06)ViewN/AView Earnings Details
11/15/2012Q312($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)
2017 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.06)($0.06)($0.06)
Q2 20171($0.06)($0.06)($0.06)
Q3 20171($0.06)($0.06)($0.06)
Q4 20172($0.07)($0.05)($0.06)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Insider Ownership Percentage: 8.79%
Institutional Ownership Percentage: 40.10%
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Patrick J McenanyInsiderBuy20,000$2.58$51,600.00View SEC Filing  
7/12/2016Charles B O'keeffeDirectorBuy20,000$0.81$16,200.00View SEC Filing  
6/17/2016Philip H CoelhoDirectorBuy15,000$0.76$11,400.00View SEC Filing  
6/14/2016Donald A DenkhausDirectorBuy50,000$0.65$32,500.00View SEC Filing  
6/14/2016Patrick J McenanyCEOBuy105,300$0.65$68,445.00View SEC Filing  
4/26/2016Charles B O'keeffeDirectorBuy20,000$0.60$12,000.00View SEC Filing  
4/26/2016Patrick J McenanyCEOBuy50,000$0.65$32,500.00View SEC Filing  
3/17/2016Philip H CoelhoDirectorBuy10,000$1.06$10,600.00View SEC Filing  
3/16/2016Charles B O'keeffeDirectorBuy10,000$1.11$11,100.00View SEC Filing  
1/11/2016Steve MillerCOOBuy7,933$1.80$14,279.40View SEC Filing  
1/8/2016Charles B O'keeffeDirectorBuy5,000$1.94$9,700.00View SEC Filing  
1/7/2016Donald A DenkhausDirectorBuy25,000$2.03$50,750.00View SEC Filing  
12/28/2015Patrick J McenanyCEOBuy25,000$2.39$59,750.00View SEC Filing  
12/23/2015Charles B O'keeffeDirectorBuy5,000$2.41$12,050.00View SEC Filing  
11/19/2015Charles B O'keeffeDirectorBuy5,000$2.30$11,500.00View SEC Filing  
10/23/2015M Douglas WinshipVPSell22,800$3.34$76,152.00View SEC Filing  
10/1/2015Patrick J McenanyCEOBuy10,000$2.81$28,100.00View SEC Filing  
5/1/2015David D MuthEVPBuy1,700$3.20$5,440.00View SEC Filing  
4/30/2015Charles B O'keeffeDirectorBuy10,000$3.29$32,900.00View SEC Filing  
4/28/2015David D MuthEVPBuy2,000$3.55$7,100.00View SEC Filing  
4/27/2015Donald A DenkhausDirectorBuy15,000$3.71$55,650.00View SEC Filing  
4/27/2015Patrick J McenanyCEOBuy5,000$3.79$18,950.00View SEC Filing  
4/24/2015Charles B O'keeffeDirectorBuy5,000$3.80$19,000.00View SEC Filing  
3/27/2015Donald A DenkhausDirectorBuy5,000$4.17$20,850.00View SEC Filing  
1/20/2015David D MuthEVPBuy21,000$2.96$62,160.00View SEC Filing  
1/13/2015Charles B O'keeffeDirectorBuy10,000$3.00$30,000.00View SEC Filing  
1/8/2015Patrick J McenanyCEOBuy50,000$2.80$140,000.00View SEC Filing  
10/3/2014David D MuthVPBuy10,000$2.65$26,500.00View SEC Filing  
6/4/2014Steve MillerCOOBuy100,000$2.17$217,000.00View SEC Filing  
5/21/2014Patrick McenanyCEOBuy25,000$1.89$47,250.00View SEC Filing  
5/19/2014Charles O'keeffeDirectorBuy10,000$1.83$18,300.00View SEC Filing  
4/16/2014Charles O'keeffeDirectorBuy5,000$2.02$10,100.00View SEC Filing  
2/7/2014Patrick McenanyCEOBuy25,000$1.82$45,500.00View SEC Filing  
2/5/2014Charles O'keeffeDirectorBuy10,000$1.81$18,100.00View SEC Filing  
10/23/2013David S TierneyDirectorBuy8,000$2.03$16,240.00View SEC Filing  
10/21/2013Charles B O'keeffeDirectorBuy10,000$1.84$18,400.00View SEC Filing  
10/21/2013Patrick J McenanyCEOBuy50,000$1.59$79,500.00View SEC Filing  
2/19/2013Patrick J McenanyCEOBuy50,000$0.46$23,000.00View SEC Filing  
12/17/2012Patrick J McenanyCEOBuy100,000$0.45$45,000.00View SEC Filing  
12/8/2012Biomarin Pharmaceutical IncMajor ShareholderBuy5,000,000$0.75$3,750,000.00View SEC Filing  
11/15/2012Patrick J McenanyCEOBuy100,000$0.42$42,000.00View SEC Filing  
11/15/2012Philip H CoelhoDirectorBuy24,000$0.41$9,840.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Latest Headlines for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Source:
DateHeadline
finance.yahoo.com logoCatalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum
finance.yahoo.com - October 16 at 6:14 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (CPRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 12 at 12:20 AM
americanbankingnews.com logoCatalyst Pharmaceuticals (CPRX) versus Endocyte (ECYT) Head to Head Review
www.americanbankingnews.com - September 30 at 2:24 PM
americanbankingnews.com logoShort Interest in Catalyst Pharmaceuticals, Inc. (CPRX) Declines By 35.4%
www.americanbankingnews.com - September 29 at 1:28 AM
americanbankingnews.com logo-$0.06 Earnings Per Share Expected for Catalyst Pharmaceuticals, Inc. (CPRX) This Quarter
www.americanbankingnews.com - September 22 at 4:28 PM
nasdaq.com logoCatalyst (CPRX) Focused on Two Lead Pipeline Candidates - Nasdaq
www.nasdaq.com - September 19 at 10:31 PM
finance.yahoo.com logoCatalyst (CPRX) Focused on Two Lead Pipeline Candidates
finance.yahoo.com - September 18 at 5:28 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (CPRX) Insider Patrick J. Mcenany Purchases 20,000 Shares
www.americanbankingnews.com - September 5 at 4:46 PM
americanbankingnews.com logoCatalyst Pharmaceuticals' (CPRX) Buy Rating Reiterated at SunTrust Banks, Inc.
www.americanbankingnews.com - September 5 at 9:42 AM
americanbankingnews.com logo Analysts Expect Catalyst Pharmaceuticals, Inc. (CPRX) to Announce -$0.06 Earnings Per Share
www.americanbankingnews.com - September 3 at 10:24 PM
nasdaq.com logoCatalyst Pharmaceuticals Provides Update on the Status of its ... - Nasdaq
www.nasdaq.com - August 31 at 10:22 PM
streetinsider.com logoCatyalyst Pharma (CPRX) Provides Update on the Status of its Firdapse; Sees NDA Submitted in First Quarter of 2018
www.streetinsider.com - August 31 at 5:21 PM
globenewswire.com logoCatalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities - GlobeNewswire (press release)
globenewswire.com - August 30 at 6:31 PM
finance.yahoo.com logoCatalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities
finance.yahoo.com - August 30 at 6:31 PM
nasdaq.com logoCatalyst (CPRX) Focused on Development of Pipeline Candidates
www.nasdaq.com - August 15 at 6:12 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. to Post Q4 2017 Earnings of ($0.05) Per Share, SunTrust Banks Forecasts (NASDAQ:CPRX)
www.americanbankingnews.com - August 14 at 6:42 AM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 11:04 PM
seekingalpha.com logoCatalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 6:46 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target at Roth Capital
www.americanbankingnews.com - August 10 at 3:22 PM
nasdaq.com logoCatalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update - Nasdaq
www.nasdaq.com - August 9 at 5:38 PM
finance.yahoo.com logoCatalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 5:38 PM
finance.yahoo.com logoCatalyst reports 2Q loss
finance.yahoo.com - August 9 at 5:38 PM
nasdaq.com logoWhat's in Store for Catalyst (CPRX) This Earnings Season? - Nasdaq
www.nasdaq.com - August 9 at 3:15 AM
zacks.com logoWhat's in Store for Catalyst (CPRX) This Earnings Season?
www.zacks.com - August 7 at 10:54 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (CPRX) Given a $6.00 Price Target by Piper Jaffray Companies Analysts
www.americanbankingnews.com - August 7 at 6:20 PM
nasdaq.com logoCatalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Th
www.nasdaq.com - August 2 at 4:18 AM
finance.yahoo.com logoCatalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10th, 2017
finance.yahoo.com - August 1 at 6:12 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:14 AM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (CPRX) Short Interest Down 16.0% in July
www.americanbankingnews.com - July 28 at 1:25 AM
americanbankingnews.com logoShort Interest in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Rises By 213.4%
www.americanbankingnews.com - July 14 at 7:04 AM
benzinga.com logo10 Biggest Mid-Day Losers For Thursday | Benzinga - Benzinga
www.benzinga.com - July 13 at 6:42 PM
thestreet.com logoCommit To Purchase Catalyst Pharmaceuticals At $2.50, Earn 73% Annualized Using Options - TheStreet.com
www.thestreet.com - July 12 at 11:12 PM
bizjournals.com logoBiotech Stocks Ride Momentum in Anticipation of Favorable Governmental Policy Environment
www.bizjournals.com - July 12 at 6:09 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Nektar Therapeutics and Catalyst Pharmaceuticals Inc.
finance.yahoo.com - July 12 at 6:09 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (CPRX) Expected to Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - July 5 at 11:48 AM
zacks.com logoWhy is Catalyst Pharmaceuticals' Stock Up 160% this Year?
www.zacks.com - June 28 at 5:25 PM
globenewswire.com logoCatalyst Pharmaceuticals Joins Russell 3000 Index - GlobeNewswire (press release)
globenewswire.com - June 26 at 10:18 PM
nasdaq.com logoWhy Is Catalyst Pharmaceuticals (CPRX) Up 25.5% Since the Last Earnings Report?
www.nasdaq.com - June 14 at 5:21 PM
nasdaq.com logoCatalyst Pharmaceuticals (CPRX) Shares March Higher, Can It Continue?
www.nasdaq.com - June 8 at 1:46 AM
seekingalpha.com logoCatalyst Pharmaceuticals (CPRX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 1:46 AM
globenewswire.com logoCatalyst Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 1 at 10:05 PM
globenewswire.com logoCatalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium - GlobeNewswire (press release)
globenewswire.com - May 19 at 8:35 AM
nasdaq.com logoCatalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium - Nasdaq
www.nasdaq.com - May 18 at 11:01 AM
zacks.com logoCatalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1
www.zacks.com - May 11 at 5:04 PM
globenewswire.com logoCatalyst Pharmaceuticals Announces Poster Presentation of MuSK ... - GlobeNewswire (press release)
globenewswire.com - May 10 at 9:48 PM
globenewswire.com logoCatalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 11th ... - GlobeNewswire (press release)
globenewswire.com - May 4 at 9:35 PM
nasdaq.com logoCatalyst Pharmaceuticals to Hold First Quarter Financial Results ... - Nasdaq
www.nasdaq.com - May 3 at 8:29 AM
nasdaq.com logoWhat's in Store for Catalyst (CPRX) Stock in Q1 Earnings?
www.nasdaq.com - May 2 at 7:45 PM
nasdaq.com logoCatalyst (CPRX) Up 16.6% Since Earnings Report: Can It Continue?
www.nasdaq.com - April 19 at 12:43 PM
prnewswire.com logoResearch Reports Coverage on Generic Drugs Stocks -- Innocoll, Catalyst Pharma, Galectin Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - April 18 at 12:17 PM

Social

Chart

Catalyst Pharmaceuticals (CPRX) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.